Stocks · News reference
8-K filing — NEOGENOMICS INC (NEO)
Filed: 2026-07-28 AccNo: 0001077183-26-000058 Size: 727 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
Greenland Mines Outlines $2B Valuation for Sarfartoq Project
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.
NeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.